Immune
Thymosin Alpha-1
Also called Thymalfasin, Zadaxin, Tα1
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in roughly 35 countries, though never the US.
Work out your draw
These numbers are a starting point — change any of them.
- Concentration
- 0.8mg/mL
- Volume per draw
- 2mL
- Units to dial
- 200
- Doses per cartridge
- 1
This is 200 units, past the 60-unit dial. Splitting it across administrations, or using less water to raise the concentration, brings it back into range.
Dial range varies by pen; 1–60 units is the common configuration.
Vial label
Copy this into your label printer.
Published research contexts for Thymosin Alpha-1 describe 1.6–1.6 mg per administration. Descriptive only, not a recommendation.
Roughly 2 hours in plasma.
An immune-modulating peptide licensed as a medicine in roughly 35 countries but never in the US. Human dosing was subcutaneous, so a schedule table is shown; the amount matches the chronic hepatitis B study and the Zadaxin label.
Dosing schedule
How Thymosin Alpha-1 is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Reported scheduleThe amount and spacing given to trial participants in the chronic hepatitis B study and carried on the Zadaxin label. | 1.6 mg | Twice weekly | SubQ |
Modelled level — 2x per week
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 10hours
- Administrations
- 2/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Andreone P et al., Hepatology 1996A placebo-controlled study of chronic hepatitis B gave thymosin alpha-1 1.6 mg subcutaneously twice weekly to trial participants over about six months.
- Zadaxin (thymalfasin) product labelLicensed as a medicine in roughly 35 countries; the label lists 1.6 mg subcutaneously twice weekly.